Advertisement

Topics

Gilead Forges NASH Deal With insitro as It Continues to Take Aim at the Liver Disease

20:00 EDT 15 Apr 2019 | BioSpace

Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.

Original Article: Gilead Forges NASH Deal With insitro as It Continues to Take Aim at the Liver Disease

NEXT ARTICLE

More From BioPortfolio on "Gilead Forges NASH Deal With insitro as It Continues to Take Aim at the Liver Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...